You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD20-Positive Lymphoid Malignancies

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non-Hodgkin's Lymphoma (Disorder), Acute Lymphoid Leukemia, Disease (Disorder) Trial in Louisville, Houston (1A46 Injection)

Recruiting
  • Non-Hodgkin's Lymphoma (Disorder)
  • Acute Lymphoid Leukemia, Disease (Disorder)
  • 1A46 Injection
  • Louisville, Kentucky
  • +1 more
Aug 1, 2022

Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia Refractory, B-cell Lymphoma Recurrent Trial in São Paulo

Not yet recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +5 more
  • São Paulo, Brazil
    Hospital Israelita Albert Einstein
Jan 20, 2023

Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell Trial run by the National Cancer Institute

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Anti-CD19 and anti-CD20 bicistronic CAR T- cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Apr 10, 2023

Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia Trial

Recruiting
  • Recurrent Acute Lymphoblastic Leukemia
  • +15 more
  • Anti-CD19/CD20/CD22 CAR T-Cells
  • +2 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Nov 4, 2022

Advanced Malignancies Trial in Beijing (1A46 Drug Substance)

Not yet recruiting
  • Advanced Malignancies
  • 1A46 Drug Substance
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Aug 4, 2023

CD19-positive Relapsed or Refractory B-cell Malignancies Trial in Hefei (UTAA09 cells for infusion, Fludarabine,

Not yet recruiting
  • CD19-positive Relapsed or Refractory B-cell Malignancies
  • UTAA09 cells for infusion
  • +2 more
  • Hefei, Anhui, China
    The First Affiliated Hospital of USTC (AnHui Provincial Hospital
Oct 13, 2023

Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Huntsville, Bethesda (Ublituximab,

Terminated
  • Non-Hodgkins Lymphoma
  • +6 more
  • Huntsville, Alabama
  • +1 more
May 5, 2022

CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies Trial in Hefei (T cell injection targeting CD7 chimeric

Recruiting
  • CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies
  • T cell injection targeting CD7 chimeric antigen receptor
  • Hefei, Anhui, China
    PersonGen.Anke Cellular Therapeutice Co., Ltd.
Dec 24, 2021

B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL Trial in Louisville (Cyclophosphamide, Fludarabine, ACE1831)

Recruiting
  • B-cell Lymphoma
  • +5 more
  • Louisville, Kentucky
    Norton Cancer Institute
Jan 24, 2023

Lymphoma, B-Cell, Lymphoma, Non-hodgkins, Chronic Lymphocytic Leukemia Trial run by the NCI (Anti-cluster of differentiation 19

Terminated
Has Results
  • Lymphoma, B-Cell
  • +3 more
  • Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptors (CAR) and Anti-cluster of differentiation 20 (CD20)-CAR T cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 26, 2022

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Chronic Lymphocytic Leukemia Trial in Milwaukee (CAR-20/19-T cells (1.0 x10^5

Completed
Has Results
  • Lymphoma, Non-Hodgkin
  • +3 more
  • CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg)
  • +3 more
  • Milwaukee, Wisconsin
    Froedtert Hospital & Medical College of Wisconsin
Jun 26, 2022

R/R CD19-Positive B-Cell Malignancies, Indolent Non-Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma Trial (CNTY-101, IL-2,

Recruiting
  • R/R CD19-Positive B-Cell Malignancies
  • +2 more
  • CNTY-101
  • +2 more
  • Detroit, Michigan
  • +1 more
Dec 21, 2022

T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia Trial in Beijing, Shenzhen,

Recruiting
  • T-cell Acute Lymphoblastic Leukemia
  • +3 more
  • Universal CD7-specific CAR gene-engineered T cells
  • Beijing, Beijing, China
  • +2 more
Aug 17, 2023

CD20-positive Non-Hodgkin Lymphoma Trial in China (EX103 injection)

Recruiting
  • CD20-positive Non-Hodgkin Lymphoma
  • EX103 injection
  • Zhengzhou, Henan, China
  • +3 more
Aug 28, 2023

CD20-positive Non-Hodgkin Lymphoma Trial in Seoul (Rituximab + MG4101)

Terminated
  • CD20-positive Non-Hodgkin Lymphoma
  • Rituximab + MG4101
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Oct 24, 2022

CD20-positive B-cell Non-Hodgkin's Lymphoma Trial in Beijing (IMM0306)

Recruiting
  • CD20-positive B-cell Non-Hodgkin's Lymphoma
  • Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Apr 6, 2023

T Lymphoblastic Leukemia/Lymphoma, T-cell Acute Lymphoblastic Leukemia, Peripheral T Cell Lymphoma Trial in Shanghai (anti-CD7

Recruiting
  • T Lymphoblastic Leukemia/Lymphoma
  • +4 more
  • anti-CD7 CAR-T cells
  • Shanghai, China
    Xianmin General Song
Aug 29, 2022

Hematologic Malignancies Trial in Zhengzhou (RD13-02 cell infusion)

Recruiting
  • Hematologic Malignancies
  • RD13-02 cell infusion
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Jun 26, 2023

Non-hodgkin Lymphoma, Acute Lymphoblastic Leukaemia, Chronic Lymphocytic Leukemia Trial in Tianjin (CC312)

Recruiting
  • Non-hodgkin Lymphoma
  • +2 more
  • CC312
  • Tianjin, Tianjin, China
    InstituteHBDH
Sep 12, 2023

Resolved Hepatitis B, CD20 Positive B-cell Lymphoma Trial (Entecavir)

Not yet recruiting
  • Resolved Hepatitis B
  • CD20 Positive B-cell Lymphoma
  • (no location specified)
Jul 10, 2022

B-cell Non Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia Trial in Milwaukee (Dose Level -1: 0.75x10^6 cells/kg

Recruiting
  • B-cell Non Hodgkin Lymphoma
  • B-cell Chronic Lymphocytic Leukemia
  • Dose Level -1: 0.75x10^6 cells/kg CAR20.19.22 cells
  • +3 more
  • Milwaukee, Wisconsin
    Medical College of Wisconsin and Froedtert Hospital
Jul 1, 2022

Relapsed/Refractory, High Risk Hematologic Malignancies, T-ALL/Lymphoma Trial in Langfang (CD7CAR T cells)

Recruiting
  • Relapsed/Refractory, High Risk Hematologic Malignancies
  • T-ALL/Lymphoma
  • CD7CAR T cells
  • Langfang, Hebei, China
    Hebei Yanda Lu Daopei Hospital
Jun 30, 2022

Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia Trial in Cleveland (Fully human anti CD19 CAR-T

Recruiting
  • Non Hodgkin Lymphoma
  • +2 more
  • Fully human anti CD19 CAR-T Cell Dose
  • +2 more
  • Cleveland, Ohio
    University Hospitals Cleveland Medical Center, Case Comprehensiv
Oct 4, 2022

Tumors, Hematologic Tumors, Tumors by Site Trial in Wuhan (RD13-02 cell infusion)

Recruiting
  • Neoplasms
  • +3 more
  • RD13-02 cell infusion
  • Wuhan, Hubei, China
    Union Hospital, Huazhong University of Science and Technology
Jun 8, 2023

Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma Trial in United States (P-CD19CD20-ALLO1, Rimiducid)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • +5 more
  • La Jolla, California
  • +7 more
Aug 25, 2023